Float Short %

36.85

Margin Of Safety %

Put/Call OI Ratio

0.36

EPS Next Q Diff

-0.07

EPS Last/This Y

1.28

EPS This/Next Y

0.38

Price

10.13

Target Price

22.12

Analyst Recom

2.22

Performance Q

-50.44

Relative Volume

0.73

Beta

2.1

Ticker: NTLA

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	NTLA	9.31	0.37	0.44	122347
2025-12-10	NTLA	9.39	0.37	0.18	123233
2025-12-11	NTLA	9.55	0.37	0.42	123955
2025-12-12	NTLA	9.02	0.36	0.12	126309
2025-12-15	NTLA	9.15	0.36	0.44	126139
2025-12-16	NTLA	9.11	0.36	0.45	127407
2025-12-17	NTLA	8.86	0.36	0.13	127528
2025-12-18	NTLA	8.88	0.36	0.18	127237
2025-12-19	NTLA	9.25	0.36	0.26	126517
2025-12-22	NTLA	9.66	0.37	0.21	111623
2025-12-23	NTLA	9.41	0.37	0.34	113449
2025-12-26	NTLA	9.44	0.36	0.26	114845
2025-12-29	NTLA	9.15	0.36	0.93	115629
2025-12-30	NTLA	9.07	0.37	0.09	116210
2025-12-31	NTLA	8.98	0.35	0.52	116674
2026-01-02	NTLA	9.25	0.35	0.34	116755
2026-01-05	NTLA	9.39	0.35	1.06	117303
2026-01-06	NTLA	9.75	0.36	0.14	118124
2026-01-07	NTLA	10.12	0.36	0.27	118457
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	NTLA	9.30	24.3	14.8	-3.97
2025-12-10	NTLA	9.39	24.3	-7.0	-3.97
2025-12-11	NTLA	9.56	24.3	-15.0	-3.97
2025-12-12	NTLA	9.03	24.3	42.1	-3.97
2025-12-15	NTLA	9.14	24.3	-9.5	-3.97
2025-12-16	NTLA	9.14	24.3	3.0	-3.97
2025-12-17	NTLA	8.80	24.3	27.7	-3.97
2025-12-18	NTLA	8.87	24.3	-6.8	-3.97
2025-12-19	NTLA	9.25	24.3	-32.4	-3.97
2025-12-22	NTLA	9.72	24.3	-35.2	-3.97
2025-12-23	NTLA	9.44	24.3	23.0	-3.97
2025-12-26	NTLA	9.44	24.0	12.8	-3.97
2025-12-29	NTLA	9.14	24.0	25.1	-3.97
2025-12-30	NTLA	9.07	24.0	6.9	-3.97
2025-12-31	NTLA	8.98	24.0	7.2	-3.97
2026-01-02	NTLA	9.23	24.0	-21.0	-3.97
2026-01-05	NTLA	9.40	24.0	-15.1	-3.97
2026-01-06	NTLA	9.75	24.0	-27.7	-3.97
2026-01-07	NTLA	10.13	24.0	-30.6	-3.97
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	NTLA	1.44	4.96	36.61
2025-12-10	NTLA	1.44	4.96	40.56
2025-12-11	NTLA	1.44	4.96	40.56
2025-12-12	NTLA	-0.07	4.96	40.56
2025-12-15	NTLA	-0.07	4.96	40.40
2025-12-16	NTLA	-0.08	4.96	40.40
2025-12-17	NTLA	-0.08	4.96	40.40
2025-12-18	NTLA	-0.08	4.96	40.40
2025-12-19	NTLA	-0.08	4.96	40.40
2025-12-22	NTLA	-0.08	4.97	40.48
2025-12-23	NTLA	-0.07	4.97	40.48
2025-12-26	NTLA	-0.07	4.97	36.85
2025-12-29	NTLA	-0.07	4.97	36.85
2025-12-30	NTLA	-0.07	4.97	36.85
2025-12-31	NTLA	-0.07	4.97	36.85
2026-01-02	NTLA	-0.07	4.97	36.85
2026-01-05	NTLA	0.04	4.97	36.85
2026-01-06	NTLA	0.04	4.97	36.85
2026-01-07	NTLA	1.22	4.97	36.85
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.92

Avg. EPS Est. Current Quarter

-0.97

Avg. EPS Est. Next Quarter

-0.99

Insider Transactions

1.22

Institutional Transactions

4.97

Beta

2.1

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-96.4

Target Price

22.12

P/E

Forward P/E

PEG

P/S

20.4

P/B

1.57

P/Free Cash Flow

EPS

-4.27

Average EPS Est. Cur. Y

-3.97

EPS Next Y. (Est.)

-3.59

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-774.94

Relative Volume

0.73

Return on Equity vs Sector %

-86.6

Return on Equity vs Industry %

-71.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

-30.6

Intellia Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 403

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

stock quote shares NTLA – Intellia Therapeutics, Inc. Stock Price stock today

news today NTLA – Intellia Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NTLA – Intellia Therapeutics, Inc. yahoo finance google finance

stock history NTLA – Intellia Therapeutics, Inc. invest stock market

stock prices NTLA premarket after hours

ticker NTLA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NTLA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y